Stocks logged solid gains this week, as the Dow Jones Industrial Average (DJINDICES:^DJI) jumped 3.8% and the S&P 500 (SNPINDEX:^SPX) rose 2.5%. Investors processed a flood of earnings reports while watching for signs of progress on a new stimulus bill aimed at blunting the economic impact of the COVID-19 pandemic.
Several highly anticipated earnings reports are due over the next several trading days, including Tilray (NASDAQ:TLRY), DraftKings (NASDAQ:DKNG), and Royal Caribbean (NYSE:RCL). Below, I’ll take a look at the key trends that might send their stocks moving next week.
Image source: Getty Images.
Royal Caribbean’s sinking revenue
With its entire fleet under a no-sail order from the CDC, analysts envision some brutal operating numbers from Royal Caribbean in its Monday earnings report. The second quarter spans April, May, and June. Due to the lack of sailings during that period, investors expect revenue to plunge to near zero, compared to $2.8 billion of sales a year ago. Rival Norwegian Cruise Lines last week reported that revenue dove to just $17 million in Q2, compared to $1.7 billion a year ago.
Royal Caribbean’s last operating update contained a few bright spots, including the fact that bookings appeared to be going strong for 2021 sailings. It was early in the season for these purchases in mid-May, though. CEO Richard Fain and his team should have more details to share about how next year’s outlook is shaping up.
Beyond that forecast, look for Royal Caribbean to discuss its plans for how to safely resume sailings once regulators clear the industry. Consumers appear eager to get back to cruise vacations, but even one more ship-based COVID-19 outbreak could easily set demand back for Royal Caribbean and its peers.
Tilray’s shrinking losses
Cannabis specialist Tilray will announce its results on Monday afternoon, and expectations are low heading into this report. The Canada-based marijuana producer announced good news on the growth front in the first quarter, as sales more than doubled to $52 million. Tilray notched gains in each of its core business lines, including recreational and medical cannabis. Its hemp product sales surged, too. But investors chose to focus instead on the company’s significant — and persistent — net losses.
CEO Brendan Kennedy and his team said in mid-May that Tilray is planning to change that trend and achieve positive adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) by the end of 2020. Progress on that score will be one of the biggest factors influencing Wall Street’s reaction to Monday’s report. Most analysts who follow the stock expect much slower sales growth this quarter, with…
Read More:3 Things to Watch in the Stock Market Next Week | The Motley Fool
